Nevertheless, even if unadjusted pool estimations showed a trend toward better ORR outcomes among patients who received either NMA or post-infusional IL2, multivariate model did not demonstrate any higher likelihood of tumor response in these subsets. This evidence concerns the gene IL2 and neoplasm.